Francesco Bax1,2, Christian Lettieri3, Alessandro Marini3,4, Gaia Pellitteri3,4, Andrea Surcinelli3,4, Mariarosaria Valente3,4, Riccardo Budai3, Vincenzo Patruno5, Gian Luigi Gigli3,4. 1. Department of Neurosciences, Udine University Hospital, Udine, Italy. bax.francesco@spes.uniud.it. 2. Department of Medicine (DAME), University of Udine, Udine, Italy. bax.francesco@spes.uniud.it. 3. Department of Neurosciences, Udine University Hospital, Udine, Italy. 4. Department of Medicine (DAME), University of Udine, Udine, Italy. 5. Pneumology Unit, Udine University Hospital, Udine, Italy.
Abstract
OBJECTIVE: To report clinical and electroneuromyographic (ENMG) characteristics of patients affected by severe COVID-19 infection, evaluated for muscular weakness. MATERIALS AND METHODS: ENMGs performed for evaluation of diffuse weakness in patients who could not be discharged from semi-intensive care COVID unit because of difficulties in ventilation weaning were reviewed. Patients with severe COVID-19 infection who had undergone endotracheal intubation and able to co-operate were considered. ENMG protocol was focused on neurophysiological items that excluded or confirmed critical illness polyneuropathy (CIP), myopathy (CIM), or polyneuromyopathy (CIPM). Standardized clinical evaluation was performed using Medical Research Council (MRC) sum score. RESULTS: Eight patients were included in the study. All presented known risk factors for intensive care unit-acquired weakness (ICU-AW), and none of them had history of underlying neuromuscular disorders. ENMG findings were normal in two patients, while only two patients had an altered MRC sum score (< 48). Neuromuscular involvement was diagnosed in 6/8 patients (75%): 2 had CIP, 1 had possible CIM, 1 had CIPM, while 1 patient, with clinically evident weakness but equivocal ENMG findings, was classified as ICU-AW. Finally, 1 patient was diagnosed with acute demyelinating neuropathy. Patients with neuromuscular involvement were those with longer intubation duration and higher levels of IL-6 at admission. CONCLUSION: Neuromuscular complications are frequent in severe COVID-19 and cannot be excluded by MRC sum scores above 48. Standardized ENMG is helpful in guiding diagnosis when clinical evaluation is not reliable or possible. Elevated IL-6 at admission may be a predictor biomarker of ICU-AW in COVID-19.
OBJECTIVE: To report clinical and electroneuromyographic (ENMG) characteristics of patients affected by severe COVID-19infection, evaluated for muscular weakness. MATERIALS AND METHODS: ENMGs performed for evaluation of diffuse weakness in patients who could not be discharged from semi-intensive care COVID unit because of difficulties in ventilation weaning were reviewed. Patients with severe COVID-19infection who had undergone endotracheal intubation and able to co-operate were considered. ENMG protocol was focused on neurophysiological items that excluded or confirmed critical illness polyneuropathy (CIP), myopathy (CIM), or polyneuromyopathy (CIPM). Standardized clinical evaluation was performed using Medical Research Council (MRC) sum score. RESULTS: Eight patients were included in the study. All presented known risk factors for intensive care unit-acquired weakness (ICU-AW), and none of them had history of underlying neuromuscular disorders. ENMG findings were normal in two patients, while only two patients had an altered MRC sum score (< 48). Neuromuscular involvement was diagnosed in 6/8 patients (75%): 2 had CIP, 1 had possible CIM, 1 had CIPM, while 1 patient, with clinically evident weakness but equivocal ENMG findings, was classified as ICU-AW. Finally, 1 patient was diagnosed with acute demyelinating neuropathy. Patients with neuromuscular involvement were those with longer intubation duration and higher levels of IL-6 at admission. CONCLUSION: Neuromuscular complications are frequent in severe COVID-19 and cannot be excluded by MRC sum scores above 48. Standardized ENMG is helpful in guiding diagnosis when clinical evaluation is not reliable or possible. Elevated IL-6 at admission may be a predictor biomarker of ICU-AW in COVID-19.
Authors: Esther Witteveen; Luuk Wieske; Tom van der Poll; Marike van der Schaaf; Ivo N van Schaik; Marcus J Schultz; Camiel Verhamme; Janneke Horn Journal: Crit Care Med Date: 2017-06 Impact factor: 7.598
Authors: Yusuf A Rajabally; Marie-Christine Durand; James Mitchell; David Orlikowski; Guillaume Nicolas Journal: J Neurol Neurosurg Psychiatry Date: 2014-05-09 Impact factor: 10.154
Authors: Robert D Stevens; Scott A Marshall; David R Cornblath; Ahmet Hoke; Dale M Needham; Bernard de Jonghe; Naeem A Ali; Tarek Sharshar Journal: Crit Care Med Date: 2009-10 Impact factor: 7.598
Authors: Eric A Liu; Tomas Salazar; Elisa Chiu; Talya K Fleming; Leslie Bagay; David P Brown; Sara J Cuccurullo Journal: Am J Phys Med Rehabil Date: 2022-02-01 Impact factor: 2.159
Authors: Domenico Intiso; Antonello Marco Centra; Antonio Giordano; Andrea Santamato; Luigi Amoruso; Filomena Di Rienzo Journal: J Rehabil Med Date: 2022-04-07 Impact factor: 2.912